Press Releases

Adamis Pharmaceuticals Announces Presentation of Results of a Human Factors Study Conducted With Its Newly Approved Epinephrine Pre-filled Syringe at the American Academy of Allergy, Asthma and Immunology (AAAAI) Joint Congress With the World Allergy Organization

SAN DIEGO, Dec. 01, 2017 — Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) (“Adamis”) announced today the acceptance of a presentation entitled “Human Factors Study of A Newly Approved Epinephrine Prefilled Syringe (Symjepi) for the Emergency Treatment of Allergic Reactions (Type I) Including Anaphylaxis”. The presentation will be for the American Academy of Allergy, Asthma, and Immunology (AAAAI) joint congress with the World Allergy Organization and will be held in Orlando, Florida on March 3, 2018. This premier annual educational event draws thousands of healthcare professionals including allergists, immunologists and other medical specialists.

Dr. Dennis J. Carlo, President/CEO of Adamis stated, “Symjepi was studied in trained and untrained adults, adolescents and caregivers. The results definitively showed Symjepi to be an easy to use, small and intuitive device.” Dr. Ronald Moss, Chief Medical Officer at Adamis and a Fellow of AAAAI stated, “For a layperson, treatment of anaphylaxis with a simple non-threatening device is critical to successful use.” The presentation will focus on the successful human factors study utilizing Symjepi.

About Adamis Pharmaceuticals

Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company focused on developing and commercializing products in the therapeutic areas of respiratory disease and allergy. The company’s first product, Symjepi (epinephrine) Injection 0.3mg, was approved in June 2017 for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis’ product pipeline includes HFA metered dose inhaler and dry powder inhaler products for the treatment of bronchospasm and asthma.
The Company’s U.S. Compounding, Inc. (USC) subsidiary, which is registered as a drug compounding outsourcing facility under Section 503B of the U.S. Food, Drug & Cosmetic Act and the U.S. Drug Quality and Security Act, compounds sterile prescription drugs, and certain nonsterile drugs, to patients, physician clinics, hospitals, surgery centers and other clients throughout most of the United States.

Adamis Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future results of operations, including, but not limited to the following statements: the status of anticipated presentations by the company at upcoming conferences; the company’s beliefs concerning the ability of its products and product candidates to compete successfully in the market; the company’s beliefs concerning the results of studies relating to Symjepi and user perceptions of Symjepi; and the company’s beliefs concerning the safety and effectiveness of its products and product candidates. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, which may cause Adamis’ actual results to be materially different from those contemplated by these forward-looking statements. Certain of these risks, uncertainties, and other factors are described in greater detail in Adamis’ filings from time to time with the SEC, which Adamis strongly urges you to read and consider, all of which are available free of charge on the SEC’s web site at Any forward-looking statement in this press release speaks only as of the date on which it is made. Except to the extent required by law, Adamis expressly disclaims any obligation to update any forward-looking statements.


Mark Flather
Senior Director, Investor Relations
& Corporate Communications
Adamis Pharmaceuticals Corporation
(858) 412-7951

Primary Logo

Adamis Pharmaceuticals logo

ADAMIS Announces Merger With DMK Pharmaceuticals

What is DMK?
Private, clinical-stage, neuro-biotech company
  • Focused on developing potential blockbuster products for underserved patients.
  • Product candidates selected and developed from proprietary library of approximately 750 small molecule neuropeptide analogues with broad utility.

Developing multiple first-in-class products targeting large unmet needs
  • Addiction
  • Acute and chronic pain
  • Parkinson’s disease
  • Bladder control
  • Other neuro-based diseases

Want to learn more?

Read our press release go to our Investor Relations page or visit

Check this page for the most recent updates regarding the merger process.